Arctic Bioscience Q1 Company Update
Highlights · Raised NOK 300 million to fund pharmaceutical development program and new production facility · Listed at Euronext Growth on February 24[th] · Signed 3-year agreement with Smerud Medical Research International for phase II study of mild to moderate psoriasis drug candidate · HRO350 pharmaceutical project developing according to plan · Initiated research collaboration for development of new drug candidate for extremely premature infants · Maintain full year revenue growth target of 40%+, mainly driven by H2 sales“The year this far has been an eventful one for